Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference

DALLAS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the Southern Regional Burn Conference (SRBC), held September 10-12, 2026 in Williamsburg, Virginia.   

The Company’s DeepView^® System for Burn Indication was on display for attending burn care clinicians and was the subject of KOL presentations that support the use of AI and multispectral imaging in the assessment of burn wounds:    

• Artificial Intelligence Evaluation of Multispectral Imaging Improves Physician Accuracy in Detecting Non-Healing Burn Wounds
  James Hwang, MD, UAB, Birmingham, AL

• Repeatability and Reproducibility of Artificial Intelligence Analysis of Burn Wound Multispectral Imaging
  Jeffrey Carter, MD, FACS,FABA, Burn and Trauma at UMCNO, New Orleans, LA

“We were pleased to engage with burn care clinicians and thought leaders at the SRBC and to showcase the DeepView System’s potential to support faster, more informed treatment decisions,” said Vincent S. Capone, Chief Executive Officer. “Following the FDA’s De Novo Classification of the DeepView System earlier this year, we remain focused on advancing adoption of our technology and supporting clinicians with immediate, objective data that can help guide patient care.”

“As burn surgeons, we are constantly making treatment decisions to optimize outcomes for our patients,” said Dr. James Hwang, Director, UAB Burn Center, Chief, Burn Service. “The significant improvement in diagnostic evaluation, with AI assistance, is encouraging and suggests that DeepView could provide valuable additional insight when making these important treatment determinations.”

About the DeepView^® System

Spectral AI's DeepView System is a non-invasive, predictive medical device that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within burn wounds. It was granted De Novo Classification by the U.S. Food and Drug Administration (“FDA”) in May 2026 and received its initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. The DeepView System provides physicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.

Upcoming Events

Midwest Region Burn Conference (MRBC)
October 22-23, 2026
Columbus, OH

The MRBC serves as a central gathering point for the burn care community across the Midwest and Eastern Great Lakes regions. It supports the professionals who care for burn patients at every stage by providing practical education, sharing best practices, and strengthening the connections that support coordinated, team-based care.

Northeast Region Burn Conference (NRBC)
November 13-14, 2026
Boston, MA

The NRBC brings together a multidisciplinary community of burn-care professionals, including physicians, nurses, physician assistants, nurse practitioners, physical therapists, occupational therapists, residents, fellows, social workers, case managers, psychologists, nutritionists, burn technicians, students, pharmacists, firefighters, education outreach personnel and other members of the burn care team.​

The NRBC will feature the following KOL presentation:

• Artificial Intelligence Evaluation of Multispectral Imaging Improves Physician Accuracy in Detecting Non-Healing Burn Wounds
  Alisa Savetamal, MD, FACS, FABA, Connecticut Burn Center, Bridgeport, CT

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com.

The Company’s contract with the Biomedical Advanced Research and Development Authority (“BARDA”) is held and performed through its wholly owned subsidiary, Spectral MD. References to the contract, associated awards, related revenue, business opportunities, obligations, and other relevant factors should be understood to refer to Spectral MD as the contracting party unless otherwise indicated.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors:
The Equity Group
Devin Sullivan	Conor Rodriguez
Managing Director	Associate
Devin.Sullivan@theequitygroup.com	Conor.Rodriguez@theequitygroup.com